Published online before print December 3, 2007, doi: 10.1161/CIRCULATIONAHA.107.702407
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Circulation. 2007;116:2913-2922.)
© 2007 American Heart Association, Inc.
Arrhythmia/Electrophysiology |
Progesterone Regulates Cardiac Repolarization Through a Nongenomic Pathway
An In Vitro Patch-Clamp and Computational Modeling Study
From the Department of Bio-Informational Pharmacology, Medical Research Institute (H.N., J.K., C.-X.B., K.A., T.F.) and Department of Cardiovascular Medicine, Graduate School of Medicine (H.N., M.I.), Tokyo Medical Research Institute, Tokyo, Japan, and Department of Physiology and Biophysics (J.X., R.V.O., Z.I.Z., C.E.C.), Institute for Computational Biomedicine, Weill Medical College of Cornell University, New York, NY.
Correspondence to Tetsushi Furukawa, MD, PhD, 2–3–10 Kandasurugadai, Chiyoda-ku, Tokyo 101–0062, Japan. E-mail t_furukawa.bip{at}mri.tmd.ac.jp
Received March 12, 2007; accepted October 12, 2007.
 |
Abstract |
|---|
 Top Abstract IntroductionMethodsResultsDiscussionReferences |
|---|
Background— Female sex is an independent risk factor for torsade de pointes in long-QT syndrome. In women, QT interval and torsade de pointes risk fluctuate dynamically during the menstrual cycle and pregnancy. Accumulating clinical evidence suggests a role for progesterone; however, the effect of progesterone on cardiac repolarization remains undetermined.
Methods and Results— We investigated the effects of progesterone on action potential duration and membrane currents in isolated guinea pig ventricular myocytes. Progesterone rapidly shortened action potential duration, which was attributable mainly to enhancement of the slow delayed rectifier K+ current (IKs) under basal conditions and inhibition of L-type Ca2+ currents (ICa,L) under cAMP-stimulated conditions. The effects of progesterone were mediated by nitric oxide released via nongenomic activation of endothelial nitric oxide synthase; this signal transduction likely takes place in the caveolae because sucrose density gradient fractionation experiments showed colocalization of the progesterone receptor c-Src, phosphoinositide 3-kinase, Akt, and endothelial nitric oxide synthase with KCNQ1, KCNE1, and CaV1.2 in the caveolae fraction. We used computational single-cell and coupled-tissue action potential models incorporating the effects of progesterone on IKs and ICa,L; the model reproduces the fluctuations of cardiac repolarization during the menstrual cycle observed in women and predicts the protective effects of progesterone against rhythm disturbances in congenital and drug-induced long-QT syndrome.
Conclusions— Our data show that progesterone modulates cardiac repolarization by nitric oxide produced via a nongenomic pathway. A combination of experimental and computational analyses of progesterone effects provides a framework to understand complex fluctuations of QT interval and torsade de pointes risks in various hormonal states in women.
Key Words: arrhythmia • computers • ion channel • long-QT syndrome • nitric oxide • progesterone
|
Introduction |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Female sex is an independent risk factor for the development of torsade de pointes (TdP) in both congenital and acquired long-QT syndrome (LQTS).1,2 In females, there are dynamic fluctuations in QT interval and TdP risk during the menstrual cycle and pregnancy. Repolarization duration is shorter in the luteal phase than in the follicular phase by
10 ms.3 QTc prolongation induced by the class III antiarrhythmic agent ibutilide is greatest during menses, intermediate in ovulation, and least in the luteal phase.4 In congenital LQTS patients, TdP risk is low during pregnancy and suddenly increases postpartum.5 In postmenopausal women, hormone replacement therapy with estrogen alone causes slight but significant prolongation of the QTc interval, whereas combinational hormone replacement therapy with estrogen and progestin consistently shortens QTc interval.6 Collectively, these clinical data suggest that the luteal hormone progesterone has protective effects against long QT–associated arrhythmias; however, very few studies have investigated the effects of progesterone on cardiac repolarization.
Clinical Perspective p 2922
We have recently reported that testosterone acutely affects cardiac repolarization by modulating slowly activating delayed rectifier K+ current (IKs) and L-type Ca2+ current (ICa,L) through the nongenomic pathway of the androgen receptor.7 Progesterone also exhibits various actions through a nongenomic pathway in several cells and tissues.8,9 In the present study, therefore, we examined the rapid effects of progesterone on action potentials and membrane currents in cardiac myocytes. We found that progesterone acutely modulated both IKs and ICa,L via a pathway involving phosphoinositide 3-kinase (PI3K)/Akt–dependent endothelial nitric oxide (NO) synthase (eNOS) activation. We also incorporated the effects of progesterone into the Faber-Rudy10 model of cardiac ventricular action potential. The model reproduces observed fluctuations of cardiac repolarization during the menstrual cycle in women. Simulations predict protective effects of progesterone against rhythm disturbance in both single-cell and coupled-tissue models of congenital and drug-induced LQTS.
|
Methods |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Details of the methods can be found in the expanded Methods section of the online-only Data Supplement.
Statistical Analysis
All numerical values are presented as mean±SEM. Statistical significance between baseline and drug application experiment was evaluated by a nonparametric test (Wilcoxon signed-rank test), and that among repeated measures between baseline and various drugs was evaluated by an ANOVA with repeated measures followed by Bonferroni’s multiple-comparison test. The Bonferroni-adjusted probability values were used. Values of P<0.05 were taken as significant.
The authors had full access to and take full responsibility for the integrity of the data. All authors have read and agree to the manuscript as written.
|
Results |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Effects of Progesterone Under Basal Conditions
To test whether the effects of progesterone vary depending on the stage of estrous cycle, we examined the effects of progesterone on action potential duration (APD) at 2 different estrous stages: at the estrous stage when the serum progesterone level is lowest and at the diestrous stage when the serum progesterone level is highest.11 We found no significant difference in progesterone effects on APD between the 2 estrous stages (supplementary Figure I); thus, we pooled data obtained from guinea pigs at different stages of the estrous cycle.
Progesterone at 100 nmol/L shortened APD (Figure 1A), and a 10-minute washout of progesterone did not reverse the effects of progesterone: APD50 was 314.9±17.5 ms at baseline, 302.4±16.6 ms after progesterone (P<0.01 versus baseline), and 303.0±16.0 ms after washout (P<0.01 versus baseline; P=NS versus progesterone) (n=7). A specific progesterone receptor inhibitor, mifepristone (1 µmol/L), reversed APD shortening: APD50 was 305.1±24.4 ms at baseline, 290.0±22.5 ms after progesterone (P<0.01 versus baseline), and 305.4±23.3 ms after mifepristone (P<0.01 versus progesterone; P=NS versus baseline) (n=6). Thus, we conclude that APD shortening by progesterone is a specific, receptor-dependent effect, and we assume that a 10-minute washout might not be long enough to achieve the reversal of progesterone, a highly lipophilic gonadal steroid.
|
To investigate the ionic mechanism underlying progesterone-induced APD shortening, we examined the effects of progesterone on IKs and ICa,L. Progesterone (100 nmol/L) enhanced IKs elicited by 3.5-second depolarizing pulses at 0.1 Hz within 5 minutes after progesterone application and reached a pseudosteady state within 10 minutes (Figure 1B, a), suggesting that this effect is acute and nongenomic. A 10-minute washout of progesterone again did not reverse IKs enhancement (Figure 1B, a). IKs enhancement by progesterone is dose dependent, with an EC50 value of 2.7 nmol/L (Figure 1B, b). To test in more physiologically relevant conditions, we examined the effects of progesterone on IKs induced by a 400-ms depolarizing pulse at 1 Hz. We tested progesterone at 2.5 nmol/L (data not shown) and 40.6 nmol/L (Figure 1B, c) because the reported serum progesterone level in women is 2.5 nmol/L in the luteal phase and 40.6 nmol/L in the follicular phase.12 The fractional increase in IKs at 1 Hz at both concentrations (1.18±0.06 at 2.5 nmol/L [n=7] and 1.35±0.04 at 40.6 nmol/L [n=4]) was similar to the values at 0.1 Hz calculated with Hill fits (1.21 at 2.5 nmol/L and 1.34 at 40.6 nmol/L). The current-to-voltage (I-V) curves showed that IKs was uniformly enhanced at all potentials tested independent of membrane potential (Figure 1B, c). Thus, the effects of progesterone on IKs were frequency or voltage independent.
In contrast, progesterone (100 nmol/L) did not significantly affect ICa,L under basal conditions (Figure 1C): current density was –7.7±0.9 pA/pF at baseline and –7.6±0.8 pA/pF after progesterone (P=NS) (n=5).
Effects of Progesterone in cAMP-Stimulated Conditions
Because sympathetic nervous system (SNS) stimulation is a critical triggering factor for TdP in LQTS patients,13 we examined the effects of progesterone on APD, IKs, and ICa,L in conditions mimicking SNS stimulation. Application of (–)-isoproterenol hydrochloride (Isp; 100 nmol/L) to the bath (extracellular) solution shortened APD, which reached a pseudosteady state within 10 minutes (Figure 2A, gray symbols). Additional application of progesterone (100 nmol/L) significantly shortened APD (Figure 2A, black symbols). In the presence of Isp, the effects of progesterone were not reversed by a 10-minute washout of progesterone. APD was 315.1±16.3 ms at baseline, 306.4±16.9 ms at 10 minutes after Isp (P=NS versus baseline), 284.9±15.3 ms after Isp and progesterone (P<0.01 versus baseline; P<0.05 versus Isp), and 282.0±17.4 ms after washout of progesterone (P<0.01 versus baseline; P<0.05 versus Isp; P=NS versus Isp and progesterone) (n=8).
|
To investigate the effects of maximal SNS activation on IKs and ICa,L, we used the whole-cell configuration of the patch-clamp technique with a pipette (intracellular) solution containing 3',5'-cAMP (cAMP; 0.2 mmol/L) and okadaic acid (0.2 µmol/L). On establishment of the whole-cell configuration, IKs started to increase in amplitude and reached a pseudosteady state within 10 minutes (Figure 2B, gray symbols). Subsequently applied progesterone at 2.5 and 40.6 nmol/L did not significantly enhance IKs tail density (Figure 2B); current density was 6.6±0.8 and 7.1±0.7 pA/pF before and after application of 2.5 nmol/L progesterone (P=NS) (n=8) and 6.6±0.9 and 7.2±0.9 pA/pF before and after application of 40.6 nmol/L progesterone (P=NS) (n=7). In contrast, progesterone (100 nmol/L) significantly suppressed cAMP-enhanced ICa,L (Figure 2C, a, black circles). Progesterone-induced ICa,L suppression was dose dependent, with an IC50 value of 29.9 nmol/L (Figure 2C, b). The effects of progesterone on the I-V curve, activation curve, and inactivation curve were obtained at 2.5 nmol/L (data not shown) and at 40.6 nmol/L (Figures 2C, c and Data Supplement Figure II). Progesterone caused a positive shift in the activation curve (Data Supplement Figure IIA); V1/2 was –24.0±2.0 mV in cAMP, –19.6±2.5 mV after progesterone (P<0.05 versus cAMP), and –18.5±2.5 mV after washout (P<0.05 versus cAMP; P=NS versus progesterone). Progesterone caused a negative shift in the inactivation curve (supplementary Figure IIB); V1/2 was –27.0±0.9 mV in cAMP, –30.9±1.2 mV after progesterone (P<0.05 versus cAMP), and –33.5±1.0 mV after washout (P<0.05 versus cAMP; P=NS versus progesterone) (n=7). Thus, APD shortening by progesterone under SNS-stimulated conditions is due mainly to the modulation of gating kinetics of ICa,L, which results in a net reduction in depolarizing Ca2+ current.
Signal Pathway for Progesterone Effects
We have previously reported that phytoestrogen, ginsenoside Re, enhanced IKs through the nongenomic pathway of progesterone receptor (PgR) involving c-Src, PI3-kinase, Akt, and eNOS.14 We performed a series of pharmacological experiments to test whether a similar signaling pathway mediated the progesterone-induced IKs enhancement. The reagents used included inhibitors for PgR (mifepristone), Akt (TAT-Akt inhibitor peptide [Akt-in]), PI3-kinase [2-(4-morpholinyl)-8-phenyl-1(4H)-benzopyran-4 to 1 hydrochloride (LY294,002)], and eNOS (L-N5-(1-lminoethy)ornithine [L-NIO]) and the NO scavenger 2-(4-carboxyphenyl)-4,5-dihydro-4,4,5,5-tetramethyl-1H-imidazol-1-yloxy-3-oxide (carboxy-PTIO).
After preincubation with mifepristone (1 µmol/L; Figure 3A) or intracellular dialysis of Akt-in (500 µmol/L) in the whole-cell patch-clamp configuration (Figure 3B), progesterone (100 nmol/L) failed to increase IKs tail currents. In the presence of mifepristone, IKs density was 2.4±0.3 and 2.3±0.3 pA/pF before and after application of progesterone (P=NS) (n=5); in the presence of Akt-in, IKs density was 3.1±0.4 and 3.0±0.4 pA/pF before and after application of progesterone (P=NS) (n=5). After progesterone (100 nmol/L) enhanced IKs tail currents, subsequent application of LY294,002 (30 µmol/L; Figure 3C), L-NIO (1 µmol/L; Figure 3D), or carboxy-PTIO (100 µmol/L; Figure 3E) decreased IKs tail current density to the level before progesterone application. IKs density was 1.8±0.2 pA/pF at baseline, 2.6±0.5 pA/pF after progesterone (P<0.05 versus baseline), and 1.9±0.3 pA/pF after progesterone and LY294,002 (P=NS versus baseline; P<0.05 versus progesterone) (n=5); it was 2.8±0.1 pA/pF at baseline, 4.8±0.5 pA/pF after progesterone (P<0.05 versus baseline), and 3.0±0.2 pA/pF after progesterone and L-NIO (P=NS versus baseline; P<0.05 versus progesterone) (n=5); and those values were 4.1±0.8 pA/pF at baseline, 6.4±0.5 pA/pF after progesterone (P<0.05 versus baseline), and 4.1±0.7 pA/pF after progesterone and carboxy-PTIO (P=NS versus baseline; P<0.05 versus progesterone) (n=5). These data indicate that progesterone-induced IKs enhancement was caused by NO, which was released via the c-Src/PI3-kinase/Akt–dependent eNOS activation. We also found that progesterone suppressed cAMP-induced ICa,L via eNOS-induced NO release (supplementary Figure III).
|
Caveolae Localization of Molecules Involved in the Nongenomic Pathway of Progesterone
We next determined the localization of molecules involved in the nongenomic pathway of progesterone using sucrose density gradient fractionation experiments in the absence (Figure 4A) and presence (Figure 4B) of progesterone. In the absence of progesterone, caveolin-3, a caveolae maker, migrated mainly to fraction 5, indicating that fraction 5 is the caveolae fraction in our experimental condition. A majority of KCNQ1 (
subunit of the IKs channel) and eNOS comigrated with caveolin-3 to fraction 5. CaV1.2 ( subunit of the ICa,L channel), KCNE1 (β subunit of the IKs channel), c-Src, p85 (a regulatory subunit of PI3-kinase), and Akt localized rather broadly between fractions 4 and 11 and/or cytoplasmic fraction; however, a substantial fraction of these molecules localized to the caveolae fraction (fraction 5). Although neither the full-length PgR-A (94 kDa) nor PgR-B (116 kDa) was detected in any membrane fractions or the cytosolic fraction, an antibody against the C terminus of PgR detected truncated forms of the PgR at 78 kDa (PR78) and 54 kDa (PR54) that migrated mainly to the caveolae fraction. Thus, a substantial fraction of each of the molecules involved in the nongenomic pathway of progesterone clustered in the caveolae fraction.
|
In hearts perfused with progesterone (100 nmol/L) for 10 minutes, although localization of most of the molecules was not affected, PR78 and PR54 exhibited changes in localization (Figure 4B, a). After a 10-minute incubation with progesterone, PR78 and PR54 migrated broadly between fractions 5 and 11. Densitometric analysis revealed that the fraction of PR78 and PR54 localized in fraction 5 was significantly smaller in the presence of progesterone compared with its absence. For PR78, it was 0.54±0.07 and 0.13±0.04 in the absence (n=5) and presence (n=4) of progesterone (P<0.05); the corresponding values for PR54 were 0.41±0.09 and 0.20±0.02, respectively (P<0.05).
Computational Modeling for the Effects of Progesterone on IKs, ICa,L, APD, and QT
We next investigated the physiological effects of progesterone on cardiac action potentials by carrying out simulations in the Faber-Rudy10 model of the guinea pig myocyte. Figure 5A shows the effects of cAMP alone and with progesterone (40.6 nmol/L) on IKs and ICa,L on the basis of our experimental data. cAMP results in a large increase in IKs (Figure 5A, a, gray circle). Progesterone application causes an additional, albeit more subtle, increase (Figure 5A, a, black circle). cAMP application increases ICaL (Figure 5A, b, gray circle), but additional application of progesterone abolishes the effect (Figure 5A, b, black circle). Notice the agreement between the simulation and experiments (shown in Figure 2B, b, and 2C, a).
|
We next investigated how the effects of progesterone on IKs and ICa,L influence APD. Both in the absence (Figure 5B, a) and presence (Figure 5B, b) of SNS stimulation, the model predicts the progesterone-induced APD shortening in a dose-dependent manner. The magnitude of progesterone-induced APD shortening in patch-clamp experiments (6.3%) is in good agreement with the APD shortening in the simulation study (7.2%).
We also computed the effects of progesterone and SNS stimulation in 1-dimensional strands of coupled cells (100 cells; 1 cm) (Figure 5C, a, no progesterone; Figure 5C, b, 40.6 nmol/L progesterone; and Figure 5C, c, 40.6 nmol/L progesterone and SNS stimulation) (details of simulations are contained in the supplementary Methods section) and computed signal averages (pseudo-ECGs) of gradients of depolarization and repolarization (Figure 5C, right). As shown in Figure 5C, the shortening of the APDs as a result of the effect of progesterone alone and SNS stimulation and progesterone in the simulated tissue results in a reduction of QT interval (from 225 ms in control conditions) to 205 ms (8.8%) and 180 ms (20.0%), respectively.
Protective Effects Against Arrhythmia in a Computer Modeling
Because the model reproduces the effects of progesterone on APD in patch-clamp experiments with good accuracy, we next used this model to predict the effects of progesterone on LQTS-associated arrhythmia susceptibility. To examine the effects on SNS-induced arrhythmias, we used the D76N KCNE1 mutation linked to congenital LQTS5. The D76N KCNE1 mutation reduces the current and renders the IKs channel insensitive to β-adrenergic stimulation15; thus, probands carrying the D76N KCNE1 mutation readily develop TdP with SNS stimulation.16 In the absence of progesterone, the mutant cells are unable to adapt to the fast pacing frequency because IKs fails to increase in response to the SNS stimulation, leading to action potentials marked by stimulus artifacts resulting from insufficient repolarization (Figure 6A, top). Interestingly, in the presence of 2.5 nmol/L progesterone, which corresponds to the serum level in the follicular phase in women, little improvement is observed (Figure 6A, middle); in the presence of 40.6 nmol/L progesterone (the luteal phase), a failed SNS stimulation response is compensated for by the action of progesterone alone to increase IKs (Figure 6A, bottom). It should be noted that with continued pacing, 2.5 nmol/L progesterone also eventually causes sufficient APD shortening via buildup of IKs channels in the open state to allow the simulated cell to respond to each stimulus. In simulated 1-dimensional tissue (Figure 6A, a and 6B, b), propagation of action potentials is affected by progesterone application. In Figure 6A, the pacing artifacts that are apparent in single cells in the absence of progesterone (Figure 6A, left) are rapidly extinguished in the fiber (Figure 6A, a) near the stimulus end and fail to propagate (gray circle). Interestingly, in the presence of 40.6 nmol/L progesterone (Figure 6A, b), the fiber readily responds to the rapid pacing frequency, as seen in the single cells. Computed electrograms (pseudo-ECGs) from the fibers in Figure 6A, a and 6A, b clearly show the generation of 2 QRS and T complexes when 40.6 nmol/L progesterone is applied. In the absence of progesterone, the second stimulus fails to propagate and is observed as a notch in the tail of the T wave of the computed electrogram.
|
We next investigated the effects of progesterone on drug-induced arrhythmias. Severe early afterdepolarizations were induced by 50% block of IKr at a slow heart rate (30 bpm) (Figure 6B, top). At 2.5 nmol/L progesterone, some improvement is observed (Figure 6B, middle); at 40.6 nmol/L progesterone, the early afterdepolarizations are abolished, and the action potential morphology is normalized (Figure 6B, bottom). When we ran the same simulations in coupled tissue (Figure 6B, right), we observed preservation of the abnormalities and propagation of early afterdepolarizations in the tissue. The simulation suggested that even in coupled tissue, 40.6 nmol/L progesterone is sufficient to normalize action potential morphology in the presence of 50% IKr block.
|
Discussion |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Accumulating clinical data suggest protective effects of progesterone against LQTS-associated arrhythmias,3–6 but to the best of our knowledge, its effects on cardiac repolarization had not previously been reported. In the present article, we report 4 findings regarding the effects of progesterone on cardiac repolarization that we believe to be novel: (1) progesterone modulates IKs and ICa,L through a nongenomic pathway involving c-Src/PI3K/Akt–dependent eNOS activation; (2) progesterone enhances IKs under basal condition, whereas it inhibits ICa,L only when ICa,L is enhanced by cAMP; (3) substantial fractions of molecules involved in the nongenomic pathway of progesterone colocalize in the caveolae fraction; and (4) incorporating the effects of progesterone into a simulated myocyte and a coupled-tissue strand reproduces the observed fluctuations of cardiac repolarization duration during the menstrual cycle in women and predicts the protective effects of progesterone against rhythm disturbance in both single-cell and coupled-tissue models of congenital and drug-induced LQTS.
Although nongenomic actions of progesterone have been reported in various cells and tissues,8,9 we believe the present study to be the first to demonstrate nongenomic actions of progesterone in cardiac myocytes. Progesterone-induced IKs enhancement was inhibited by LY294002, Akt-inhibitor peptide, L-NIO, and carboxy-PTIO, and progesterone-induced suppression of cAMP-enhanced ICa,L was inhibited by L-NIO and carboxy-PTIO. Thus, progesterone exhibits its effects via NO produced through the nongenomic pathway involving PI3-kinase and eNOS. Our sucrose density gradient fractionation experiments demonstrate that substantial fractions of c-Src, Akt, eNOS, PR78, PR54, KCNQ1, KCNE1, and CaV1.2 are colocalized in the caveolae fraction.
Molecular identity for the PgR responsible for the nongenomic action is currently undetermined, but several candidates have been reported. One candidate is PR78 because injection of PR78 mRNA into oocytes rapidly accelerates progesterone-induced mitogen-activated protein kinase activation and oocyte maturation.17 In the present experiments, we demonstrate the presence of PR78 in cardiac myocytes and its localization to the caveolae with KCNQ1, KCNE1, CaV1.2, and eNOS. Immunocytochemical experiments revealed that PgR located mainly to the T tubule and, at least in part, colocalized with caveolin-3 (Data Supplement Figure IV). Sucrose gradient experiments also showed that progesterone application shifted the localization of PR78 and PR54 to broad membrane fractions but not to the cytosolic or nuclear fraction. Immunocytochemical experiments showed that progesterone did not induce translocation of PgR into nucleus. These findings are in line with the idea that PR78 is responsible for nongenomic actions at least in cardiomyocytes. However, further studies are certainly required to determine whether PR78 and/or newly identified PR54 is the receptor specific for the nongenomic pathway in cardiac myocytes and to clarify the physiological implication of ligand-induced translocation of PR78 and PR54 within plasma membrane.
We found that SNS stimulation differentially modulated the progesterone effects on IKs and ICa,L. Under basal conditions, progesterone affected only IKs, whereas under cAMP-stimulated conditions, progesterone clearly reversed cAMP-induced enhancement of ICa,L. This difference could be explained by differential mechanisms of NO to modulate IKs and ICa,L. We have previously suggested that NO-induced ICa,L suppression was attributable to cGMP-dependent pathway, whereas NO-induced IKs enhancement was via a cGMP-independent pathway.18 The former agrees with the previous finding that cGMP counteracts cAMP-induced ICa,L enhancement.19
We incorporated the effects of progesterone on IKs and ICa,L in the Faber-Rudy10 model of the guinea pig ventricular myocyte. The model predicts that 40.6 nmol/L progesterone, a serum level corresponding to that of the luteal phase in women, shortens APD by 3.7% under basal conditions and 4.6% under SNS-stimulated conditions compared with APD at 2.5 nmol/L progesterone (the level in the follicular phase). Clinically observed QT intervals are shorter by 2.4% to 2.8% in the luteal phase than in follicular phase,3 so the APD shortening predicted in the model (3.7% to 4.6%) fits well with the observed fluctuation in QT interval during the menstrual cycle in women. We also investigated the effects of progesterone and SNS stimulation in simulated coupled tissue and computed virtual electrograms from simulated gradients of depolarization and repolarization. Simulations suggest that during the luteal phase when progesterone is 40.6 nmol/L, maximal SNS stimulation may additionally shorten the QT interval by 12.2%. These simulations support the notion that progesterone may exert protective QT shortening effects under conditions of SNS stimulation.
From these results, we then used the model to predict the effects of progesterone on SNS-induced rhythm disturbance in single-cell and coupled-tissue models of congenital LQTS and drug-induced LQTS. IKs exhibits accumulation in the preopen state during rapid heart rates, resulting in action potential adaptation.20 SNS stimulation enhances ICa,L to increase Ca2+ influx.21 SNS stimulation also enhances IKs, 22,23 which counterbalances ICa,L enhancement and maintains APD within a certain range.24 In LQTS1 and LQTS5, IKs channel disturbance results in dysfunction of action potential adaptation to rapid heart rates and response to SNS stimulation. Enhancement of IKs in the absence of SNS stimulation and inhibition of cAMP-induced ICa,L by progesterone improve action potential adaptation in our simulations in single cells and coupled tissue. Drug-induced TdP is believed to occur by blockade of the human ether-a-go-go related gene (hERG) channel by drugs with various structures.25 Progesterone does not have apparent effects on IKr (data not shown); thus, the predicted protection against drug-induced early afterdepolarizations may be attributed to an increase in repolarization reserve by IKs enhancement.26
Our electrophysiological and molecular biological studies demonstrate a novel effect of progesterone on cardiac repolarization. The biological experimental analysis, combined with a computational analysis of effects of progesterone on cardiac repolarization, provides a framework to understand the dynamic natures of QT interval and TdP risks in various hormonal states, particularly given the complex interaction with multiple factors, including SNS status, heart rate, QT-prolonging drugs, and gene mutations.
|
Acknowledgments |
|---|
We thank S. Oishi for collecting data and E. Ozaki, M. Hayashi, and K. Watanabe for technical assistance.
Sources of Funding
This work was supported in part by grant-in-aid 17081007 (Dr Furukawa) for scientific research on priority areas; grants 18390231 (Dr Furukawa) and 19689006 (Dr Kurokawa) from the Ministry of Education, Culture, Sports, Science, and Technology of Japan; and a research grant from the Mitsui Kousei Foundation (Dr Furukawa) and the Naito Foundation (Dr Kurokawa). The research also was supported by grants from the American Heart Association, National Institutes of Health NHLBI RO1-HL-085592, and Alfred P. Sloan Foundation to Dr Clancy.
Disclosures
None.
|
References |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
1. Makkar RR, Fromm BS, Steinman RT, Meissner MD, Lehmann MH. Female gender as a risk factor for torsades de pointes associated with cardiovascular drugs. JAMA. 1993; 270: 2590–2597.
2. Locati EH, Zareba W, Moss AJ, Schwartz PJ, Vincent GM, Lehmann MH, Towbin JA, Priori SG, Napolitano C, Robinson JL, Andrews M, Timothy K, Hall WJ. Age- and sex-related differences in clinical manifestations in patients with congenital long-QT syndrome: findings from the International LQTS Registry. Circulation. 1998; 97: 2237–2244.
3. Nakagawa M, Ooie T, Takahashi N, Taniguchi Y, Anan F, Yonemochi H, Saikawa T. Influence of menstrual cycle on QT interval dynamics. Pacing Clin Electrophysiol. 2006; 29: 607–613.[CrossRef][Medline] [Order article via Infotrieve]
4. Rodriguez I, Kilborn MJ, Liu XK, Pezzullo JC, Woosley RL. Drug-induced QT prolongation in women during the menstrual cycle. JAMA. 2001; 285: 1322–1326.
5. Seth R, Moss AJ, McNitt S, Zareba W, Andrews ML, Qi M, Robinson JL, Goldenberg I, Ackerman MJ, Benhorin J, Kaufman ES, Locati EH, Napolitano C, Priori SG, Schwartz PL, Towbin JA, Vincent GM, Zhang L. Long QT syndrome and pregnancy. J Am Coll Cardiol. 2007; 49: 1092–1098.
6. Kadish AH, Greenland P, Limacher MC, Frishman WH, Daugherty SA, Schwartz JB. Estrogen and progestin use and the QT interval in postmenopausal women. Ann Noninvasive Electrocardiol. 2004; 9: 366–374.[CrossRef][Medline] [Order article via Infotrieve]
7. Bai CX, Kurokawa J, Tamagawa M, Nakaya H, Furukawa T. Nontranscriptional regulation of cardiac repolarization currents by testosterone. Circulation. 2005; 112: 1701–1710.
8. Ehring GR, Kerschbaum HH, Eder C, Neben AL, Fanger CM, Khoury RM, Negulescu PA, Cahalan MD. A nongenomic mechanism for progesterone-mediated immunosuppression: inhibition of K+ channels, Ca2+ signaling, and gene expression in T lymphocytes. J Exp Med. 1998; 188: 1593–1602.
9. Mendiberri J, Rauschemberger MB, Selles J, Massheimer V. Involvement of phosphoinositide-3-kinase and phospholipase C transduction systems in the non-genomic action of progesterone in vascular tissue. Int J Biochem Cell Biol. 2006; 38: 288–296.[CrossRef][Medline] [Order article via Infotrieve]
10. Faber GM, Rudy Y. Action potential and contractility changes in [Na+]i overloaded cardiac myocytes: a simulation study. Biophys J. 2000; 78: 2392–2404.[Medline] [Order article via Infotrieve]
11. Lilley KG, Epping RJ, Hafner LM. The guinea pig estrous cycle: correlation of vaginal impedance measurements with vaginal cytologic findings. Lab Anim Sci. 1997; 47: 632–637.[Medline] [Order article via Infotrieve]
12. Janse de Jonge XA, Boot CR, Thom JM, Ruell PA, Thompson MW. The influence of menstrual cycle phase on skeletal muscle contractile characteristics in humans. J Physiol (Lond). 2001; 530: 161–166.
13. Schwartz PJ, Priori SG, Cerrone M, Spazzolini C, Odero A, Napolitano C, Bloise R, De Ferrari GM, Klersy C, Moss AJ, Zareba W, Robinson JL, Hall WJ, Brink PA, Toivonen L, Epstein AE, Li C, Hu D. Left cardiac sympathetic denervation in the management of high-risk patients affected by the long-QT syndrome. Circulation. 2004; 109: 1826–1833.
14. Furukawa T, Bai C-X, Kaihara A, Ozaki E, Kawano T, Nakaya Y, Awais M, Sato M, Umezawa Y, Kurokawa J. Ginsenoside Re, a main phytosterol of Panax ginseng, activates cardiac potassium channels via a nongenomic pathway of sex hormones. Mol Pharmacol. 2006; 70: 1916–1924.
15. Kurokawa J, Chen L, Kass RS. Requirement of subunit expression for cAMP-mediated regulation of a heart potassium channel. Proc Natl Acad Sci U S A. 2003; 100: 2122–2127.
16. Splawski I, Tristani-Firouzi M, Lehmann MH, Sanguinetti MC, Keating MT. Mutations in the hminK gene cause long QT syndrome and suppress IKs function. Nat Genet. 1997; 17: 338–340.[Medline] [Order article via Infotrieve]
17. Bayaa M, Booth RA, Sheng Y, Liu XJ. The classical progesterone receptor mediates Xenopus oocyte maturation through a nongenomic mechanism. Proc Natl Acad Sci U S A. 2000; 97: 12607–12612.
18. Bai CX, Takahashi K, Masumiya H, Sawanobori T, Furukawa T. Nitric oxide-dependent modulation of the delayed rectifier K+ current and the L-type Ca2+ current by ginsenoside Re, an ingredient of Panax ginseng, in guinea-pig cardiomyocytes. Brit J Pharmacol. 2004; 142: 567–575.[CrossRef][Medline] [Order article via Infotrieve]
19. Fischmeister R, Castro L, Abi-Gerges A, Rochais F, Vandecasteele G. Species- and tissue-dependent effects of NO and cyclic GMP on cardiac ion channels. Comp Biochem Physiol A Mol Integr Physiol. 2005; 142: 136–143.[CrossRef][Medline] [Order article via Infotrieve]
20. Clancy CE, Kurokawa J, Tateyama M, Wehrens XH, Kass RS. K+ channel structure-activity relationships and mechanisms of drug-induced QT prolongation. Annu Rev Pharmacol Toxicol. 2003; 43: 441–461.[CrossRef][Medline] [Order article via Infotrieve]
21. Reuter H. Calcium channel modulation by neurotransmitters, enzymes and drugs. Nature. 1983; 301: 569–574.[CrossRef][Medline] [Order article via Infotrieve]
22. Walsh KB, Kass RS. Regulation of a heart potassium channel by protein kinase A and C. Science. 1988; 242: 67–69.
23. Marx SO, Kurokawa J, Reiken S, Motoike H, D’Armiento J, Marks AR, Kass RS. Requirement of a macromolecular signaling complex for beta adrenergic receptor modulation of the KCNQ1-KCNE1 potassium channel. Science. 2002; 295: 496–499.
24. Terrenoire C, Clancy CE, Cormier JW, Sampson KJ, Kass RS. Autonomic control of cardiac action potentials: role of potassium channel kinetics in response to sympathetic stimulation. Circ Res. 2005; 96: e25–e34.
25. Sanguinetti MC, Mitcheson JS. Predicting drug-hERG channel interactions that cause acquired long QT syndrome. Trends Pharmacol Sci. 2005; 26: 119–124.[CrossRef][Medline] [Order article via Infotrieve]
26. Roden DM. Long QT syndrome: reduced repolarization reserve and the genetic link. J Intern Med. 2006; 259: 59–69.[CrossRef][Medline] [Order article via Infotrieve]
|
Footnotes |
|---|
The online Data Supplement can be found with this article at http://circ.ahajournals.org/cgi/content/full/CIRCULATIONAHA.107.702407/DC1.
This article has been cited by other articles:
 |
|
 |
|
  R. C. Ahrens-Nicklas, C. E. Clancy, and D. J. Christini Re-evaluating the efficacy of {beta}-adrenergic agonists and antagonists in long QT-3 syndrome through computational modelling Cardiovasc Res, June 1, 2009; 82(3): 439 - 447. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Asada, J. Kurokawa, and T. Furukawa Redox- and Calmodulin-dependent S-Nitrosylation of the KCNQ1 Channel J. Biol. Chem., February 27, 2009; 284(9): 6014 - 6020. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Kurokawa, M. Tamagawa, N. Harada, S.-i. Honda, C.-X. Bai, H. Nakaya, and T. Furukawa Acute effects of oestrogen on the guinea pig and human IKr channels and drug-induced prolongation of cardiac repolarization J. Physiol., June 15, 2008; 586(12): 2961 - 2973. [Abstract] [Full Text] [PDF]
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||